JAZZ Q1 2019 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$508M+14.3% YoY

Gross Profit

$475M93.4% margin

Operating Income

$134M26.3% margin

Net Income

$85M16.8% margin

EPS (Diluted)

$1.47

QoQ Revenue Growth

+6.7%

Cash Flow

Operating Cash Flow

$202M

Free Cash Flow

$138M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$5.3B

Total Liabilities

$2.5B

Stockholders' Equity

$2.7B

Cash & Equivalents

$547M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$508M	$445M	+14.3%
Gross Profit	$475M	$411M	+15.6%
Operating Income	$134M	$88M	+52.3%
Net Income	$85M	$46M	+85.3%

Revenue Segments

Product And Services, Product Sales

$503M50%

Xyrem

$368M36%

Erwinaze And Erwinase

$61M6%

Defitelio/Defibrotide

$42M4%

Vyxeos

$29M3%

Product And Services, Royalties And Contract Revenue

$5M0%

Other Products

$4M0%

Geographic Segments

UNITED STATES

$463M91%

Europe

$35M7%

Other Countries

$10M2%